Moderna
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2010-01-01
- Employees
- 5.6K
- Market Cap
- $30.3B
- Website
- http://www.modernatx.com
- Introduction
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.
A Study to Compare mRNA-1273 Versus BNT162b2 COVID-19 Vaccines Among Immunocompromised Adults
- Conditions
- SARS-CoV-2
- First Posted Date
- 2022-05-09
- Last Posted Date
- 2022-05-09
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 124879
- Registration Number
- NCT05366322
- Locations
- 🇺🇸
Aetion Inc., New York, New York, United States
A Study of mRNA-1020 and mRNA-1030 Seasonal Influenza Vaccines in Healthy Adults
- Conditions
- Seasonal Influenza
- Interventions
- Biological: mRNA-1010Biological: mRNA-1030Biological: mRNA-1020Biological: Active Comparator
- First Posted Date
- 2022-04-18
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 572
- Registration Number
- NCT05333289
- Locations
- 🇺🇸
Foothills Research Center, Phoenix, Arizona, United States
🇺🇸Alliance for MultiSpecialty Research, Coral Gables, Florida, United States
🇺🇸Health Awareness, Inc., Jupiter, Florida, United States
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age
- Conditions
- Respiratory Syncytial Virus
- Interventions
- First Posted Date
- 2022-04-15
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 3317
- Registration Number
- NCT05330975
- Locations
- 🇺🇸
Central Research Associates Inc, Birmingham, Alabama, United States
🇺🇸Del Sol Research Management - Clinedge - PPDS, Tucson, Arizona, United States
🇺🇸Paragon Rx Clinical, Inc, Garden Grove, California, United States
An Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mRNA-3705 in Participants Previously Enrolled in Other Clinical Studies of mRNA-3705
- First Posted Date
- 2022-03-25
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 63
- Registration Number
- NCT05295433
- Locations
- 🇺🇸
UCLA Medical Center, Los Angeles, California, United States
🇺🇸Lucile Packard Children's Hospital at Stanford, Palo Alto, California, United States
🇨🇦Stollery Children's Hospital University of Alberta, Edmonton, Alberta, Canada
A Study to Evaluate the Immunogenicity and Safety of Omicron Variant Vaccines in Comparison With mRNA-1273 Booster Vaccine for COVID-19
- Conditions
- SARS-CoV-2
- Interventions
- Biological: mRNA-1273Biological: mRNA-1273.214Biological: mRNA-1273.529
- First Posted Date
- 2022-02-22
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 3548
- Registration Number
- NCT05249829
- Locations
- 🇬🇧
Aberdeen Royal Infirmary - PPDS, Aberdeen, Aberdeenshire, United Kingdom
🇬🇧Southmead Hospital, Bristol, Avon, United Kingdom
🇬🇧Wansford and Kingscliffe Practice, Wansford, Cambridgeshire, United Kingdom
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults
- Conditions
- Epstein-Barr Virus Infection
- Interventions
- Biological: Placebo
- First Posted Date
- 2021-12-20
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 867
- Registration Number
- NCT05164094
- Locations
- 🇺🇸
Medical Affiliated Research Institute, Huntsville, Alabama, United States
🇺🇸Alliance for Multispecialty Research, LLC, Norfolk, Virginia, United States
🇺🇸Smart Cures Clinical Research, Anaheim, California, United States
A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Vaccine Boosters
- Conditions
- SARS-CoV-2
- Interventions
- Biological: mRNA-1283.529Biological: mRNA-1283.211Biological: mRNA-1283Biological: mRNA-1273
- First Posted Date
- 2021-11-30
- Last Posted Date
- 2024-03-21
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 540
- Registration Number
- NCT05137236
- Locations
- 🇺🇸
MedPharmics, LLC, Phoenix, Arizona, United States
🇺🇸Research Centers of America, Hollywood, Florida, United States
🇺🇸Precision Clinical Research, Sunrise, Florida, United States
A Study to Assess the Long-term Safety and Clinical Activity of mRNA-3927 in Participants Previously Enrolled in the mRNA-3927-P101 Study
- First Posted Date
- 2021-11-23
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT05130437
- Locations
- 🇺🇸
Ronald Reagan UCLA Medical Center, Los Angeles, California, United States
🇺🇸Texas Children's Hospital, Houston, Texas, United States
🇬🇧Willink Biochemical Genetics Unit - Manchester, Manchester, England, United Kingdom
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of Age
- Conditions
- Respiratory Syncytial Virus
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-11-19
- Last Posted Date
- 2025-06-05
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 36814
- Registration Number
- NCT05127434
- Locations
- 🇺🇸
AES - DRS - Synexus Clinical Research US, Inc. - Birmingham, Birmingham, Alabama, United States
🇺🇸Accel Research Site - Achieve - Birmingham, Birmingham, Alabama, United States
🇺🇸Lakeview Clinical Research, Guntersville, Alabama, United States
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647
- Conditions
- Cytomegalovirus Infection
- Interventions
- Biological: mRNA-1647Biological: Placebo
- First Posted Date
- 2021-11-03
- Last Posted Date
- 2023-09-11
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT05105048
- Locations
- 🇺🇸
Velocity Clinical Research, North Hollywood, California, United States
🇺🇸California Research Foundation, San Diego, California, United States
🇺🇸East-West Medical Research Institute, Honolulu, Hawaii, United States